SYNTHROID (levothyroxine sodium) by AbbVie is synthesis. First approved in 2002.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
SYNTHROID (levothyroxine sodium) is an oral synthetic thyroid hormone replacement therapy indicated for hypothyroidism and thyroid cancer suppression. It works by providing exogenous T4 that peripheral tissues convert to active T3, restoring normal thyroid hormone signaling and gene transcription. This is a foundational endocrinology treatment with decades of clinical use.
Approaching loss of exclusivity with high claim volume signals defensive brand positioning and focus on retention strategies rather than growth initiatives.
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
Worked on SYNTHROID at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$355M Medicare spend — this is a commercially significant brand
Working on SYNTHROID offers stability in a foundational endocrinology franchise but limited upside growth; careers here emphasize managed care negotiation, generic defense, and patient retention rather than launch execution or expansion. This is a mature-stage role suited for professionals seeking established market management experience over high-growth innovation.